一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
环指蛋白125(RNF125)是一种泛素E3连接酶,据报道在多种癌症中发挥抑癌作用,但其在肺腺癌(LUAD)中的确切功能尚未阐明。
在本研究中,通过生物信息学分析以及LUAD和癌旁样本的免疫组化检测,证实RNF125在肺癌中显著下调。RNF125低表达与LUAD的转移状态、晚期肿瘤分期和较差的总生存期相关。功能获得和功能缺失实验结果表明,RNF125抑制LUAD细胞的增殖、集落形成、迁移和侵袭。
此外,RNF125增加了LUAD细胞对顺铂的敏感性。在机制上,RNF125与程序性细胞死亡配体1(PD-L1)相互作用并降低LUAD细胞中PD-L1的表达水平。
此外,当与RNF125沉默的LUAD细胞共培养时,Jurkat T细胞的IL-2分泌显著受到抑制。与对照LUAD细胞相比,NK-92细胞对RNF125沉默LUAD细胞的裂解作用也较弱,提示RNF125敲低增强了LUAD细胞的免疫逃逸能力。
值得注意的是,本研究结果发现RNA结合蛋白muscleblind样1(MBNL1)是LUAD中RNF125的上游调控因子。MBNL1增加了LUAD细胞中RNF125转录本的稳定性,而敲低RNF125逆转了MBNL1对LUAD细胞的抗肿瘤作用。
总之,本研究证明了RNF125在LUAD中的抑癌作用,并表明MBNL1是LUAD中RNF125的上游调控因子。这些发现有助于更好地理解LUAD进展的分子特征。
Ring finger protein 125 (RNF125), a ubiquitin E3 ligase, has been reported to act as a tumor suppressor in several cancers, but its precise function in lung adenocarcinoma (LUAD) has not been elucidated. In the present study, through bioinformatics analysis and immunohistochemistry in LUAD and non‑cancerous samples, it was demonstrated that RNF125 was significantly downregulated in lung cancer.
Low levels of RNF125 expression were associated with metastatic status, advanced tumor stage and poor overall survival in LUAD. The results of gain‑ and loss‑of‑function experiments demonstrated that RNF125 inhibited proliferation, colony formation, migration and invasion of LUAD cells.
In addition, RNF125 increased the sensitivity of LUAD cells to cisplatin.
Mechanistically, RNF125 interacted with programmed cell death ligand 1 (PD‑L1) and reduced PD‑L1 expression levels in LUAD cells.
Furthermore, IL‑2 secretion by Jurkat T cells was significantly suppressed when co‑cultured with RNF125‑silenced LUAD cells. NK‑92 cell lysis of RNF125‑silenced LUAD cells was also weaker compared with that of control LUAD cells, suggesting that RNF125 knockdown enhanced the immune evasion ability of LUAD cells.
Notably, the results of the present study identified that the RNA‑binding protein muscleblind‑like 1 (MBNL1) is the upstream regulator of RNF125 in LUAD. MBNL1 increased the stability of the RNF125 transcript in LUAD cells and knockdown of RNF125 reversed the antitumor effect of MBNL1 on LUAD cells.
In conclusion, the present study demonstrated the tumor suppressor role of RNF125 in LUAD and implicated MBNL1 as an upstream regulator of RNF125 in LUAD.
These findings contributed to an improved understanding of the molecular features of LUAD progression.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。